POLISH FINANCIAL SUPERVISION AUTHORITY

Current Report no. 52 / 2021

Date of preparation: 2021-10-08

Abbreviated name of the Issuer: MABION S.A.

Subject matter:

Information on the execution of a commercial manufacturing agreement with Novavax, Inc. for the period of 2022-2025

Legal basis: Article 17(1) of MAR – confidential information.

Content of the Report:

With reference to Current Reports no. 15/2021 of 3 March 2021 and no. 45/2021 of 23 June 2021, the Management Board of Mabion S.A. ("Company") hereby informs that on 8 October 2021, the Company entered into a commercial manufacturing agreement ("Master Contract Manufacturing Agreement", hereinafter: "Agreement") with Novavax, Inc. ("Novavax"), accompanied by a Statement of Work (hereinafter collectively referred to as "Order"), under which the Company will commercially manufacture for Novavax, in compliance with GMP (Good Manufacturing Practice) standard, a COVID-19 vaccine candidate antigen ("Product") under the working name of NVX-CoV2373.

The implementation of the Order was initiated as a consequence of the activities carried out by the Company and related to the transfer of the manufacturing process and analytical methods based on the procedures and requirements of Novavax, as well as the preparation of the Company's quality system for the implementation of the new process and product, provided for in the framework agreement entered into with Novavax of 3 March 2021, of which the Company informed in Current Report no. 15/2021.

The Agreement is unconditional and its execution and commencement of its implementation are independent of the registration procedure of the Novavax vaccine candidate on individual markets. The Agreement was signed for a fixed period of time until the end of 2025, with an option to extend it.

The total value of the Agreement during its term was estimated at USD 372 million i.e. PLN 1.46 billion according to the average exchange rate of the National Bank of Poland of 7 October 2021 (the Agreement's value was estimated based on a theoretical assumption of zero inflation during the whole term of the Agreement).

The Agreement will be implemented and settled per batch of the Product, at the unit batch price set forth in the Agreement (unit prices are subject to indexation based on future inflation). As part of the Agreement, the parties agreed on the volume and manufacturing schedule for each year in the period of 2022–2025, based on which Mabion will produce the number of Product batches required by Novavax. The manufacturing schedule was set for the entire term

of the Agreement, however the parties may agree on modifications to the schedule and to the volume of deliveries.

The completion of the agreed scope of work under the Agreement in the years to come is dependent on the Company's available production capacity, and therefore the Management Board will seek to expand the production capacity at the turn of 2022 and 2023 by two more bioreactors, so that the Company would have four bioreactors in the years 2023 – 2025 at its disposal. The Company's Management Board estimates that during the first two years of commercial manufacturing covered by the Agreement (i.e. in 2022 – 2023), it may realise approximately 40% of the total value of the Agreement, and in the following two years, *inter alia* as a result of the increased production capacity, approximately 60% of its total value.

The Parties expect that the GMP-compliant commercial manufacturing process will commence in December 2021. Until that time, the Company will carry out preparatory work specified in the Order, covering, *inter alia*, installation of additional systems and equipment, securing and controlling the quality of materials and producing commercial manufacturing documentation.

At the same time, the Company hereby informs that, acting pursuant to Article 17(4) of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC ("Market Abuse Regulation", "MAR"), on 6 October 2021 it decided to postpone public disclosure of the resolution of the Company's Management Board passed on 6 October 2021 to approve the substantially agreed provisions of the Agreement and the Statement of Work. Such decision was made by the Company due to the fact that immediate disclosure of such information (prior to the signing of the Agreement by Novavax) could be detrimental to the Company's legitimate interests by negatively affecting the Company's cooperation with Novavax. In accordance with third paragraph of Article 17(4) of MAR, after the publication hereof, the Company will provide the Polish Financial Supervision Authority with information on the postponement in disclosure of confidential information along with reasons for such postponement.